Generate Biomedicines (GENB) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 41 164 sessions, February 27, 2026 to October 21, 2026
- Largest daily move
- -20.8% close of August 26, 2026
- 1-month change
- -24.6% closing prices, September 21, 2026 to October 21, 2026
Company Description
Generate Biomedicines, Inc. develops protein therapeutics using a generative biology platform that applies machine learning to drug discovery and development. The company is a clinical-stage biotechnology issuer focused on programming novel protein medicines across therapeutic areas and modalities. Its common stock trades on Nasdaq under the symbol GENB.
The company reports a single operating segment engaged in generative biology. Its Generate Platform is designed to create and optimize protein therapeutic candidates by using computational methods to generate medicines across multiple modalities. Generate's operating model centers on advancing internally developed and partnered programs from platform discovery into clinical development.
Pipeline and therapeutic focus
Generate Biomedicines' named product candidates include GB-0895, an anti-TSLP program being developed for respiratory diseases including severe asthma and COPD; GB-4362, an MMAE neutralizer in oncology that has received FDA Fast Track designation; and GB-5267, a MUC16 armored CAR T program developed in collaboration with Roswell Park Comprehensive Cancer Center. These programs reflect the company's use of generative biology across different therapeutic modalities, including antibody-based and cellular therapy approaches.
The company's business is centered on research and development rather than commercial product sales. As a clinical-stage biotechnology company, its recurring activities include platform development, preclinical and clinical program advancement, regulatory interactions, collaboration work, and financing of research and development operations.
Public-company structure
Generate Biomedicines became a public company through an initial public offering of common stock. In connection with the IPO, the company adopted an amended and restated certificate of incorporation and amended and restated bylaws that define its public-company governance framework, authorized capital structure, stockholder meeting procedures, and board authority to issue undesignated preferred stock. The company is based in Somerville, Massachusetts.
Stock Performance
Generate Biomedicines (GENB) closed at $13.11 on October 21, 2026. Over the past month, the price has lost 24.6%.
GENB Metrics & Rankings
Price returns through October 21, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Generate Biomedicines has 9 recent news articles, with the latest published today. Of the recent coverage, 3 articles coincided with positive price movement and 4 with negative movement. Key topics include AI, clinical trial, earnings, IPO, offering. View all GENB news →
SEC Filings
Generate Biomedicines has filed 10 recent SEC filings, including 3 Form 8-K, 2 Form 144, 2 Form 10-Q, 2 Form SCHEDULE 13G. The most recent filing was submitted on September 3, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GENB SEC filings →
Insider Radar
Insider selling at Generate Biomedicines over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Upcoming Events
Guggenheim presentation
Jefferies presentation
Generate Biomedicines has 2 upcoming scheduled events. The next event, "Guggenheim presentation", is scheduled for November 9, 2026 (in 18 days). Investors can track these dates to stay informed about potential catalysts that may affect the GENB stock price.
Short Interest History
Short interest in Generate Biomedicines (GENB) currently stands at 7.4 million shares, up 3.3% from the previous reporting period, representing 6.8% of the float. Since March 2026, short interest has increased by 730.2%.
Days to Cover History
Days to cover for Generate Biomedicines (GENB) currently stands at 5.8 days, down 20.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since March 2026, the figure has increased by 475%. Across the settlements charted above, it has ranged from 1.0 to 15.3 days.
GENB Company Profile & Sector Positioning
Generate Biomedicines (GENB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.